Novavax reports net loss of $14M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring Novavax Inc. (Nasdaq:NVAX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/NVAX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

Novavax Inc. (NVAX) is a clinical-stage biotechnology company focused on creating differentiated, value-added vaccines that improve upon preventive options for a range of infectious diseases. These vaccines leverage its virus-like particle (VLP) platform technology coupled with a disposable production technology. VLPs are genetically engineered three-dimensional nanostructures, which incorporate immunologically important lipids and recombinant proteins. The Company's VLPs resemble the virus but lack the genetic material to replicate the virus. Its production technology uses insect cells rather than chicken eggs or mammalian cells.

Message Board Search for NVAX: http://www.boardcentral.com/boards/NVAX

In the report, the analyst notes:

"For the fourth quarter of 2009, NVAX reported a net loss of $14 million, or $0.15 per share, versus a net loss of $11.1 million, or $0.16 per share, in the fourth quarter of 2008. For 2009, the Company posted a net loss of $38.4 million, or $0.45 per share, compared to a net loss of $36 million, or $0.53 per share, for 2008. The Company reported that the increased loss in the comparative fourth quarter and year-over-year results was primarily attributable to the number and size of the clinical trials that were performed in 2009, compared to 2008.

"Despite reporting a big loss, NVAX president and CEO Dr. Rahul Singhvi stated that the Company made substantial progress across every part of its business and in each of its vaccine programs. According to Dr. Rahul Singhvi, NVAX ended the year with a strong scientific position that will enable it to continue to advance its pipeline products."